Whereas the GOLD 2022 report noted the efficacy of LABA+ICS in patients with moderate to very severe COPD and exacerbations, the GOLD 2023 and 2024 reports underscore, “Use of LABA+ICS in COPD ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果